Denali’s Data in Rare Enzyme Deficiency Keep It on Pace to Seek Speedy FDA Approval
Currently available therapies for Hunter syndrome don’t cross the blood-brain barrier to address cognitive symptoms of the inherited enzyme deficiency. Denali Therapeutics' technology gets its drug across the protective membrane, and the biotech plans to seek accelerated FDA approval in this rare disease.
